<?xml version="1.0" encoding="UTF-8"?>
<p id="para0026">Immunotherapy with neutralizing antibodies present in convalescent plasma proved to be safe and during the SARS, MERS and 2009 H1N1 influenza epidemics [
 <xref rid="bib0028" ref-type="bibr">28</xref>,
 <xref rid="bib0029" ref-type="bibr">29</xref>]. The feasibility of convalescent plasma transfusion to rescue severely ill patients with COVID-19 was explored in 10 patients in Wuhan, China. One dose (200 mL) of convalescent plasma was well tolerated, seemed to significantly improve clinical symptoms within 3 days and resulted in high-level neutralizing antibodies, leading to disappearance of viremia in 7 days. These results should be validated in larger cohorts, preferably with randomized trials 
 <xref rid="bib0030" ref-type="bibr">[30]</xref>.
</p>
